Reinventing neurostimulation from the patient’s perspective

The Nalu micro-IPG leverages proprietary advanced microelectronics to produce a pain management system that effectively reduces chronic intractable pain while minimizing interference with the patient’s life. Utilizing an external battery and a microIPG with the smallest footprint among commercially available IPGs may mitigate some of the most troublesome aspects of implantable neurostimulation therapy. It is truly Engineered to be more™:

durABLE
  • Nalu micro-IPG has the longest service life among commercially available IPGs in the US–18 years
  • Eliminates battery-replacement surgeries
  • Highly configurable microchip enables upgrade of system capabilities when approved
livABLE
  • Designed to fit patient’s lifestyle
  • Wearable power and control disc is easy to manage
  • Therapy Disc is easily changed for optimum flexibility
  • Smartphone control permits discreet system management
  • Patients report the system is easy to use1
comfortABLE
  • Rated comfortable by patients1-3
  • Patients describe the Therapy Disc as virtually unnoticeable1
  • Nalu micro-IPG allows a minimally invasive procedure
manageABLE
  • Extensive menu of therapy options
  • Patient discreetly controls system from smartphone
  • No need for separate device for patient remote control
  • Integrated power and control disc helps simplify system management
  • Feedback controlled energy transfer for consistent therapy output
upgradeABLE
  • Flexible nPower™ architecture redefines system upgradeability
  • System capabilities can be expanded by routine software updates
  • External components can be upgraded as technology evolves
adaptABLE
  • FDA-cleared for both SCS and PNS indications
  • Nalu micro-IPG provides more surgical options
  • Wide range of therapeutic options
  • Advanced control from familiar smartphone

“Today I used groundbreaking technology from NALU to treat a patient with CRPS of the leg and knee… The new pulse generator is SMALLER THAN MY FINGERTIP… I want to thank NALU for their years of research bringing this new technology to the market and their incredible vision and service to the chronic pain community.”

Dr. Paul Lynch, Scottsdale, AZ

The Nalu microIPG was named 2021 Implant and Tissue-Replacement device Gold Winner in the Medical Design Excellence Awards.

READ THE PRESS RELEASE

Nalu Neurostimulation System with nPower™ Technology

Implant
  • Battery free—eliminates implanted battery and the need for battery replacement surgery
  • 27 times smaller than the largest commercially available implantable pulse generator
  • Minimally invasive implantation procedure
  • IPG can be removed or discontinued by physician if desired
Peripherals

Smartphone Remote Control App

  • Allows simple and discreet adjustment of therapy by patient
  • Delivers a broad range of therapy options
  • Compatible with IOS and Android smartphones

Therapy Disc (integrated external battery and control system)

  • Removable when not needed or desired
  • Easily upgradable or replaceable without surgery

See Safety Information

Indications

The Nalu Neurostimulation System is currently FDA cleared for SCS and PNS indications.

Spinal Cord Stimulation (SCS)

This system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for permanent (long term) device.

Peripheral Nerve Stimulation (PNS)

This system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for permanent (long term) device.

All information on this website is provided for informational purposes only and is not a substitute for any professional medical advice. No information contained on the website is intended to be used for medical diagnosis or treatment.

1. Staats P, Hartley L, Mishra LN, et al. Human Comfort and Feasibility Data from a New, Miniaturized SCS System. presented at: North American Neuromodulation Society (NANS) Meeting; January 17-January 20 2019; Las Vegas.

2. Amirdelfan K, Levy R, Poree L, Staats P. Evaluation of a New, Battery-Free Microstimulator SCS System: Comfort and Ease-of-Use Data (nPower™ study). presented at: North American Neuromodulation Society (NANS) Meeting; January 23-January 26 2020; Las Vegas.

3. Amirdelfan K, Levy R, Poree L, et al. Evaluation Of a New, Battery-Free Micro-Implantable Pulse Generator SCS System: Patient Choice, Comfort and Ease-of-Use Data. presented at: North American Neuromodulation Society (NANS) Meeting; January 23-January 26 2020; Las Vegas.